Inhibikase Therapeutics (IKT) Debt Ratio (2020 - 2025)

Inhibikase Therapeutics (IKT) has 6 years of Debt Ratio data on file, last reported at 0.0 in Q2 2025.

• On a quarterly basis, Debt Ratio fell 97.52% year-over-year to 0.0 in Q2 2025; TTM through Jun 2025 was 0.0, a 97.52% decrease from a year earlier, with the FY2024 full-year figure at 0.0, down 96.94% from the prior year.
• Debt Ratio for Q2 2025 stood at 0.0, down from 0.0 in the prior quarter.
• Over the last five years, Debt Ratio for IKT reached as high as 0.1 in Q1 2021 and fell as low as 0.0 in Q2 2025.
• Historically, Debt Ratio has averaged 0.02 across 5 years, with a median of 0.01 in 2022.
• Across the five-year window, Debt Ratio jumped 526.92% in 2023 and plunged 97.52% in 2025, its largest moves.
• Year by year, Debt Ratio stood at 0.01 in 2021, then rose by 7.77% to 0.01 in 2022, then soared by 526.92% to 0.04 in 2023, then tumbled by 96.94% to 0.0 in 2024, then tumbled by 61.9% to 0.0 in 2025.
• Per Business Quant data, the three most recent Debt Ratio figures were 0.0 in Q2 2025, 0.0 in Q1 2025, and 0.0 in Q4 2024.